The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis

Medicine
Xianying WangGuoqiang Liu

Abstract

The efficacy and safety of once-weekly dipeptidyl peptidase-4 inhibitor (DPP-4i) omarigliptin as monotherapy or add on to other antihyperglycemic agents (AHAs) in patients with type 2 diabetes mellitus (T2DM) is unclear. PubMed, EMBASE, Cochrane library, and ClinicalTrials.gov were searched from the inception to January 24, 2018. Randomized controlled trials comparing omarigliptin with placebo or other AHAs in T2DM patients were included in our meta-analysis. Risk ratio (RR) and mean difference (MD) were used to evaluate the outcomes. Totally, 11 trials involving 8276 patients were satisfied with our inclusion criteria. Compared with control group, omarigliptin was associated with a significantly stronger reduction in hemoglobin A1c (HbA1c) (MD 0.38%, 95% confidence interval [CI] [0.18, 0.58], P = .0002) and fasting plasma glucose (MD 0.48 mmol/L, 95% CI [0.14 mmol/L, 0.82 mmol/L], P = .006). Omarigliptin increased the number of participants who achieved HbA1c < 7.0% compared with control group (RR 2.03, 95% CI [1.38, 2.98], P = .0003). No significant difference was found in the aspect of adverse events (RR 1.00, 95% CI [0.97, 1.03], P = .99), serious adverse events (RR 1.02, 95% CI [0.91, 1.13], P = .75), hypoglycemic events (...Continue Reading

References

Nov 18, 2005·Lancet·Andrew J M BoultonJan Apelqvist
Apr 5, 2007·Current Medical Research and Opinion·Richard E Pratley, Afshin Salsali
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Feb 22, 2011·Gastroenterology·Michael ElashoffPeter C Butler
Mar 1, 2012·Diabetes/metabolism Research and Reviews·K BakkerUNKNOWN International Working Group on Diabetic Foot Editorial Board
Mar 26, 2014·Journal of Medicinal Chemistry·Tesfaye BiftuAnn E Weber
Jan 18, 2015·European Journal of Epidemiology·Taulant MukaOscar H Franco
Jun 5, 2015·Globalization and Health·Josiemer MatteiUNKNOWN Global Nutrition Epidemiologic Transition Initiative
Jun 4, 2016·Cell and Tissue Research·Tripp LeavittMichael T Longaker
Jan 18, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Apr 28, 2017·Expert Opinion on Pharmacotherapy·Dimitrios StoimenisApostolos Tsapas
Jun 8, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ira GantzUNKNOWN Omarigliptin Study 015 Group
Jun 18, 2017·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Lieming DingFenlai Tan
Nov 15, 2017·Diabetes, Obesity & Metabolism·Andrew McGovernSimon de Lusignan
Jan 6, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Andrew McGovernSimon de Lusignan
Mar 22, 2018·Diabetes·Jianyin Long, Farhad R Danesh

❮ Previous
Next ❯

Citations

Jul 6, 2019·Frontiers in Endocrinology·Baptist Gallwitz
Sep 19, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Shereen MowakaBassam Ayoub
Jun 8, 2019·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Zhong-Ping GouPing Feng

❮ Previous
Next ❯

Software Mentioned

Stata11
Revman5
PTOSPERO

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.